Immunogen (IMGN) Remains Neutral Rated at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Immunogen, Inc. (IMGN) Misses Q4 EPS by 51c
August 1, 2014 6:34 AM EDTImmunogen, Inc. (NASDAQ: IMGN) reported Q4 EPS of ($0.83), $0.51 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $5.74 million versus the consensus estimate of $9.72 million.
For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.
... More